An fMRI and MRS based study to determine levels of different brain metabolites in Schizophrenia patients with persistent auditory verbal hallucinations.
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2023/11/060245
- Lead Sponsor
- Central Institute of Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International Classification of Disease-10th edition (ICD-10 DCR, World Health Organization, 1993).
2.Age between 18- 60 years of either sex.
3.Minimum of 1 failed antipsychotic trial specified (minimum two weeks trial with chlorpromazine equivalents of >600 mg/day) and mean number of failed trials not reported.
4.A score >3 in the global rating of auditory hallucinations on the SAPS scale.
5.Right handed.
6.Patients giving written informed consent.
1.Presence of co-morbid neurological or other psychiatric disorder(s).
2.Patient with co-morbid substance dependence, except nicotine and caffeine and having used the substance within 1 month of imaging.
3.Having any metallic implants/parts in body.
4.Subjects who have received ECT in past 6 months.
5.Patients having a history of head trauma with loss of consciousness.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. difference in the levels of N-Acetyl Aspartate (NAA), N-Acetyl Aspartyl Glutamate (NAAG), Creatine + Phosphocreatine (Cr + PCr), Glycerophosphocholine + Phosphocholine (GPC + Pecha) and Myo-inositol (mI) in mPFC of schizophrenia patients with persistent Auditory-Verbal Hallucinations (pAVH) compared to healthy adults.Timepoint: Baseline
- Secondary Outcome Measures
Name Time Method Difference in the resting-state functional connectivity of Default Mode Network between schizophrenia patients with pAVH & healthy controls.Timepoint: Baseline